SI1954281T1 - Postopek zdravljenja raka - Google Patents

Postopek zdravljenja raka

Info

Publication number
SI1954281T1
SI1954281T1 SI200631005T SI200631005T SI1954281T1 SI 1954281 T1 SI1954281 T1 SI 1954281T1 SI 200631005 T SI200631005 T SI 200631005T SI 200631005 T SI200631005 T SI 200631005T SI 1954281 T1 SI1954281 T1 SI 1954281T1
Authority
SI
Slovenia
Prior art keywords
treatment method
cancer treatment
cancer
administration
relates
Prior art date
Application number
SI200631005T
Other languages
English (en)
Inventor
Arundathy Nirmalini Pandite
Bonnie F Whitehead
Peter T C Ho
Albert Benjamin Suttle
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SI1954281T1 publication Critical patent/SI1954281T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
SI200631005T 2005-11-29 2006-11-29 Postopek zdravljenja raka SI1954281T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74030805P 2005-11-29 2005-11-29
EP06838636A EP1954281B1 (en) 2005-11-29 2006-11-29 Cancer treatment method
PCT/US2006/045777 WO2007064753A2 (en) 2005-11-29 2006-11-29 Cancer treatment method

Publications (1)

Publication Number Publication Date
SI1954281T1 true SI1954281T1 (sl) 2011-06-30

Family

ID=37847172

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631005T SI1954281T1 (sl) 2005-11-29 2006-11-29 Postopek zdravljenja raka

Country Status (12)

Country Link
US (1) US20090005406A1 (sl)
EP (2) EP1954281B1 (sl)
JP (1) JP2009517397A (sl)
AT (1) ATE500831T1 (sl)
CY (1) CY1111390T1 (sl)
DE (1) DE602006020611D1 (sl)
DK (1) DK1954281T3 (sl)
ES (1) ES2359517T3 (sl)
HR (1) HRP20110244T1 (sl)
PL (1) PL1954281T3 (sl)
SI (1) SI1954281T1 (sl)
WO (1) WO2007064753A2 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058307A1 (en) 2007-11-12 2009-05-13 Cellzome Ag Methods for the identification of JAK kinase interacting molecules and for the purification of JAK kinases
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
BR112013009701A2 (pt) 2010-10-27 2016-07-19 Novartis Ag regimes de dosagem para o tratamento de doença vascular ocular
US9278099B2 (en) * 2011-10-31 2016-03-08 Novartis Ag Pazopanib formulation
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526542A (en) 2000-12-21 2005-01-28 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
MXPA04012860A (es) 2002-06-17 2005-09-20 Smithkline Beecham Corp Proceso quimico.
US20070208023A1 (en) * 2004-04-16 2007-09-06 Smithkline Beecham Corporation Cancer Treatment Method

Also Published As

Publication number Publication date
PL1954281T3 (pl) 2011-07-29
WO2007064753A2 (en) 2007-06-07
DE602006020611D1 (de) 2011-04-21
CY1111390T1 (el) 2015-08-05
JP2009517397A (ja) 2009-04-30
EP1954281A2 (en) 2008-08-13
ATE500831T1 (de) 2011-03-15
HRP20110244T1 (hr) 2011-04-30
EP2380572A1 (en) 2011-10-26
EP1954281B1 (en) 2011-03-09
US20090005406A1 (en) 2009-01-01
WO2007064753A3 (en) 2007-11-29
ES2359517T3 (es) 2011-05-24
DK1954281T3 (da) 2011-05-16

Similar Documents

Publication Publication Date Title
PL1954281T3 (pl) Sposób leczenia raka
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
MY144750A (en) Treatment method
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
MXPA05012323A (es) Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
GB0223038D0 (en) Therapeutic compounds
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
GB0225474D0 (en) Therapeutic agents
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
TW200724159A (en) Stable emulsion composition
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200702027A1 (ru) Дерматологические композиции и соли для лечения дерматологических заболеваний
EA200900034A1 (ru) Применение ингибитора р38 киназы для лечения психиатрических расстройств
TW200626588A (en) (Arylamidoaryl)cyanoguanidine compounds
DK1684763T3 (da) 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel
GB0807094D0 (en) 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension